A flurry of recent FDA announcements and legal maneuvers has placed two popular weight-loss drugs — tirzepatide (marketed as Mounjaro and Zepbound by Eli Lilly) and semaglutide (marketed as Ozempic and Wegovy by Novo Nordisk) — at the center of a growing squabble. Patients are desperate for affordable access, compounding pharmacies see a market opportunity,…